Page 29 - Turkey Tail News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: All figures in USD unless stated otherwise The triad of Hushrooms™ formulations will be available for purchase throughout the U.S. at shroommart.com TORONTO, Feb. 4, 2021 /CNW/ - Halo Collective Inc. (" Halo" or the " Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) is pleased to announce the entering into of a partnership with Nightingale Remedies (" Nightingale") and PeakBirch Logic Inc. (" PeakBirch") (CSE:PKB, OTCQX:KTNNF, Germany: KYH2)), leveraging the group's formulation, manufacturing, and e-commerce expertise to develop and launch a line of products combining functional...

Nammex's new state-of-the-art extract facility comes online as mushroom demand ‘skyrockets’ With 80% growth each year for the last to years, demand for Nammex’s organic mushroom extracts have ‘gone through the roof’, said Jeff Chilton, CEO of Nammex, with the company’s new extraction facility coming online just in time. Pre-pandemic, demand for mushroom-based products has been increasing with data from the American Botanical Council’s 2019 Herb Market Report showing that, in the natural channel, sales of supplements containing Reishi increased 13.5% y...

NeonMind Biosciences Inc: NeonMind Appoints Dr. Frank Russo to Lead Development of Music-Based Program for Psilocybin Clinical Trials NeonMind Biosciences Inc. ( CSE: NEON) (" NeonMind") a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms, is pleased to announce that it has added Frank Russo as an advisor and consultant to assist the Company in selecting or developing music playlists for its clinical trials or for use with treatments to support optimum mental health. NeonMind Engages Music Expert Dr. Frank Russo To view an enhanced ...

NeonMind Biosciences Inc: NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity NeonMind Biosciences Inc. (CSE: NEON) (" NeonMind"), a psychedelic drug development company, is pleased to announce that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia whe...

NeonMind Biosciences Inc: NeonMind Appoints Trevor Millar as Chief Psychedelic Officer NeonMind Biosciences Inc. (CSE: NEON) (" NeonMind"), a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms and commercializing medicinal mushroom products, is pleased to announce that it has appointed Trevor Millar as Chief Psychedelic Officer of NeonMind as of January 6, 2021. NeonMind Appoints Trevor Millar as Chief Psychedelic Officer To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/7646/71548_NM-PR-...